Key result
Human platelets generate prostaglandin-esterified phospholipids via COX-1 upon activation, a process that is inhibited by low-dose aspirin supplementation or in vitro COX-1 blockade.
Human platelets acutely generate prostaglandin-esterified phospholipids via COX-1 upon activation, a process that is inhibited by low-dose aspirin.
Answers are grounded in this paper and cite their sources.
May inform aspirin's effects on platelet lipid mediators; leaves open clinical relevance in thrombosis pending human validation.
Oxidized phospholipids (oxPLs) generated nonenzymatically display pleiotropic biological actions in inflammation. Their generation by cellular cyclooxygenases (COXs) is currently unknown. To determine whether platelets generate prostaglandin (PG)-containing oxPLs, then characterize their structures and mechanisms of formation, we applied precursor scanning-tandem mass spectrometry to lipid extracts of agonist-activated human platelets. Thrombin, collagen, or ionophore activation stimulated generation of families of PGs comprising PGE₂ and D₂ attached to four phosphatidylethanolamine (PE) phospholipids (16:0p/, 18:1p/, 18:0p/, and 18:0a/). They formed within 2 to 5 min of activation in a calcium, phospholipase C, p38 MAP kinases, MEK1, cPLA₂, and src tyrosine kinase-dependent manner (28.1 ± 2.3 pg/2 × 10⁸ platelets). Unlike free PGs, they remained cell associated, suggesting an autocrine mode of action. Their generation was inhibited by in vivo aspirin supplementation (75 mg/day) or in vitro COX-1 blockade. Inhibitors of fatty acyl reesterification blocked generation significantly, while purified COX-1 was unable to directly oxidize PE in vitro. This indicates that they form in platelets via rapid esterification of COX-1 derived PGE₂/D₂ into PE. In summary, COX-1 in human platelets acutely mediates membrane phospholipid oxidation via formation of PG-esterified PLs in response to pathophysiological agonists.
No takes yet. Share an insight, caveat, or question.
Aldrovandi et al. (2013) studied this question. Aspirin supplementation or COX-1 blockade was evaluated on Generation of prostaglandin-esterified phospholipids. Human platelets generate prostaglandin-esterified phospholipids via COX-1 upon activation, a process that is inhibited by low-dose aspirin supplementation or in vitro COX-1 blockade.
Synapse has enriched 10 related papers. Consider them for comparative context: